Act4Biosimilars

The #Act4Biosimilars Deep Dive Report highlights opportunities to drive biosimilar adoption in Middle East and Africa, including: 🧭 Clear guidelines to ensure informed transitions to biosimilars 🛣️ Rigorous regulatory pathways to uphold high standards of biosimilar safety 📚 More education and awareness of the value of biosimilars Download the Deep Dive Report to read more about these challenges and how regional stakeholders can overcome them: https://lnkd.in/ewpihABQ #PatientAccess #HealthEquity

Curious about biosimilar adoption in the Middle East and Africa? 🤓 Take a look at the newly launched #Act4Biosimilars Deep Dive Report for the region! The Report explores the challenges that need to be overcome to increase biosimilar adoption and expand patient access to potentially life-saving biologic medicines. Regional stakeholders can use the learnings from the Report to focus their efforts where they are needed most and to achieve lasting impact. Together, we can drive change. Join the movement and download the Act4Biosimilars Deep Dive Report for MEA today. 👇 https://lnkd.in/ewpihABQ #HealthEquity #Biosimilars

Coming soon: the #Act4Biosimilars Deep Dive Report for Middle East and Africa. 🌍 Exploring the challenges preventing biosimilar adoption across the region, the Report provides analysis and actionable guidance. Some of the challenges highlighted include: 🩺Regulatory processes that do not differentiate between biosimilars and biocopies, impacting the Affordability of biosimilars 🗨️ Limited education on the value of biosimilars, affecting their Acceptability 📑 A lack of clear guidelines on transitioning to biosimilars, limiting their Accessibility Join the movement today by downloading the Action Plan: https://lnkd.in/ewhPTEWj #Healthcare #Biosimilars

Let’s take a look at biosimilar adoption across the Middle East and Africa region.🔎 We are launching a Deep Dive Report exploring the challenges to adoption in relation to the 4As of biosimilars: 👉Approvability 👉Accessibility 👉Acceptability 👉Affordability The Act4Biosimilars’ Impact Index, which measures the favorability of local policies, regulatory systems, and key stakeholders’ perceptions, highlights that Acceptability and Affordability must be in focus to expand patient access to biosimilars. Stay tuned for the Report, which delves deeper into the regional challenges impacting the 4As.📚 In the meantime, join the movement by downloading the Action Plan today: https://lnkd.in/ewhPTEWj #Act4Biosimilars #HealthcareInnovation #HealthEquity

#Act4Biosimilars has a Mission to increase the global adoption of biosimilars by at least 30 percentage points in 30+ countries by 2030. To reach this Mission, Act4Biosimilars has developed a global Action Plan to drive change no matter where a country is on its biosimilar journey. 🌍 The regional Deep Dive Reports spotlight country-specific challenges and provides guidance on how to drive change by using the Action Plan to tackle those preventing greater biosimilar adoption. Last year we launched Reports focused on the Americas and Europe regions. Stay tuned for the soon-to-launch Middle East and Africa Report. 👀 These Reports provide insights around the changes needed to give more patients access to biologics and offers stakeholders the tools needed to increase biosimilar adoption. Join the movement by downloading the Action Plan today: https://lnkd.in/ewhPTEWj #Healthcare #PatientAccess

Exciting news! The next Act4Biosimilars Deep Dive Report is launching soon. 👀 Following Reports looking at challenges in the Americas and Europe regions last year, the next Deep Dive will highlight the challenges for biosimilar adoption in the Middle East and Africa. The countries featured are: 📍Egypt 📍Morocco 📍Pakistan 📍Kingdom of Saudi Arabia 📍South Africa 📍Türkiye 📍United Arab Emirates Follow us for more of the latest information ahead of the launch of the next Deep Dive Report. #Act4Biosimilars #Biosimilars #HealthEquity

A recent PMLiVE article by Zorana Maravic, #Act4Biosimilars Steering Committee member and CEO of Digestive Cancers Europe explores how education can unlock the potential of biosimilars in Europe. "Biosimilars offer a beacon of hope for patients in many countries with little to no access to biologics’,” Zorana writes. “However, there are disparities in Accessibility and Acceptability across Europe, which mean many countries who need biosimilars most are unable to access them. Unlocking the potential of biosimilars in Europe for patients begins with education for all. Ensuring similar materials are available for all therapy areas and translated into local languages will be a big step toward improving the acceptability of biosimilars across Europe." The newly launched Act4Biosimilars Deep Dive Report for Europe highlights this challenge and the growing disparity between Eastern and Western Europe. Join the movement and download the Deep Dive Report here: https://lnkd.in/ebebrvC5 #HealthEquity #PatientEducation

“Improved understanding and education will lead to increased biosimilar adoption”, writes Laura Wingate, member of the Act4Biosimilars Steering Committee and Executive Vice President, Education, Support & Advocacy, Crohn’s & Colitis Foundation. In the first of a new Blog series called ‘Biosimilar Voices’, Laura emphasizes the importance of the patient voice in the conversation about biosimilar education and recognizes the important role of healthcare professionals to inform and support patients when they start or transition to a biosimilar medicine. Biosimilar education is a vital part of the Act4Biosimilars Action Plan and is needed to achieve the Mission to increase the global adoption of biosimilars by at least 30 percentage points in 30+ countries by 2030. Read more in Laura’s article here on the newly launched Biosimilar Voices webpage, where we’ll be sharing regular articles on important topics impacting biosimilars: https://lnkd.in/e6UC79eh You can also follow Act4Biosimilars to keep up to date with the initiative! #Act4Biosimilars #HealthEquity #PatientEducation 

The #Act4Biosimilars Deep Dive Report highlights the top 3 challenges affecting biosimilar adoption in Europe: 💶Diversity in pricing and reimbursement of biosimilars between countries, leading to inequitable access. 💰The preference for tenders which is based largely on price and often with only a single winner. 📝The disparity in physicians’ access to information about biosimilars. Download the Deep Dive Report to read more about these challenges and how we can overcome them together: https://lnkd.in/ebebrvC5 #Biosimilars #HealthEquity

Europe – are you interested in accelerating biosimilar adoption in your region?    The #Act4Biosimilars Deep Dive Report for Europe has just been published!  This highlights the specific challenges that need to be tackled to support greater biosimilar adoption, leading to increased patient access to crucial biologic treatments. Designed to be used with the Action Plan, the report provides the strategies, tools, and activities required to spark change. To realize Act4Biosimilars’ Mission of increased biosimilar adoption, your support is needed because a multistakeholder approach is crucial to address the challenges across the healthcare and regulatory landscape.  During #GlobalBiosimilarsWeek, join the movement to expand access for patients and take action by downloading the #Act4Biosimilars Deep Dive Report for Europe today. 👇 https://lnkd.in/ebebrvC5 #HealthEquity